Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

OPDUALAG

NIVOLUMAB;RELATLIMAB-RMBW

Standard Dose
240MG;80MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview OPDUALAG is listed in Drugs@FDA under application 761234 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient NIVOLUMAB;RELATLIMAB-RMBW Form and strength SOLUTION;INTRAVENOUS - 240MG;80MG Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2024-03-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview OPDUALAG is listed in Drugs@FDA under application 761234 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient NIVOLUMAB;RELATLIMAB-RMBW Form and strength SOLUTION;INTRAVENOUS - 240MG;80MG Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2024-03-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.